Anzeige
Mehr »
Mittwoch, 19.11.2025 - Börsentäglich über 12.000 News
Baltikum rüstet massiv auf: 500 Mio. Abwehrprogramm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JWL4 | ISIN: NO0010598683 | Ticker-Symbol: HBQ
Stuttgart
19.11.25 | 11:14
0,130 Euro
+2,36 % +0,003
1-Jahres-Chart
HOFSETH BIOCARE ASA Chart 1 Jahr
5-Tage-Chart
HOFSETH BIOCARE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1330,17113:51

Aktuelle News zur HOFSETH BIOCARE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.11.Hofseth BioCare ASA: Publication of the Prospectus - Start of the Subscription Period for the Subsequent Offering2
07.11.Hofseth BioCare ASA: Terms of the Subsequent Offering-
07.11.Hofseth Biocare ASA: Third Quarter 2025 Financial Report76HBC recorded total operating revenues of NOK 54.9 million in the third quarter of 2025, compared to NOK 67.9 million in the same period last year. Net operating revenues were NOK 54.8 million, reflecting...
► Artikel lesen
30.10.Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING3
28.10.XFRA CAPITAL ADJUSTMENT INFORMATION - 28.10.2025179Das Instrument 5YW CA07135M2031 BATTERY X METALS INC. EQUITY wird ex Kapitalmassnahme gehandelt am 28.10.2025 The instrument 5YW CA07135M2031 BATTERY X METALS INC. EQUITY is traded ex capital adjustment...
► Artikel lesen
27.10.Hofseth BioCare ASA: Mandatory Notification of Trade2
27.10.Hofseth BioCare ASA: Private placement successfully placed7
27.10.Hofseth Biocare ASA: Ex. Subsequent Offering Today2
HOFSETH BIOCARE Aktie jetzt für 0€ handeln
27.10.Hofseth BioCare ASA: Key Information Relating to Subsequent Offering2
27.10.Hofseth BioCare ASA: Disclosures of Large Shareholdings2
24.10.Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio126NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION...
► Artikel lesen
24.10.Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio291NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION...
► Artikel lesen
17.09.Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER9
09.09.Hofseth Biocare ASA: ProGo, the world's first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways109HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs...
► Artikel lesen
04.09.Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn9
22.08.Hofseth Biocare ASA: Second Quarter 2025 Financial Report178HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million, compared...
► Artikel lesen
16.07.Hofseth Biocare ASA: HBC's ProGo has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago5
23.05.Hofseth Biocare ASA: Annual General Meeting completed1
16.05.Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT796HBC recorded total operating revenues of NOK 60.9 million in the first quarter of 2025, compared to NOK 52.4 million in the same period last year. Net operating revenues were NOK 60.7 million, reflecting...
► Artikel lesen
21.02.Hofseth Biocare ASA: HBC Accelerates In Human Health And Pet Nutrition Through A Strategic Partnership With Symrise To Build Out Berkåk, Tripling The Manufacturing Capacity Of The Group560HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1